Search Results - "Multiple sclerosis"

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition by Walton, Clare, King, Rachel, Rechtman, Lindsay, Kaye, Wendy, Leray, Emmanuelle, Marrie, Ruth Ann, Robertson, Neil, La Rocca, Nicholas, Uitdehaag, Bernard, van der Mei, Ingrid, Wallin, Mitchell, Helme, Anne, Angood Napier, Ceri, Rijke, Nick, Baneke, Peer

“…High-quality epidemiologic data worldwide are needed to improve our understanding of disease risk, support health policy to meet the diverse needs of people…”
Get more information

Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course by Kalb, Rosalind, Brown, Theodore R, Coote, Susan, Costello, Kathleen, Dalgas, Ulrik, Garmon, Eric, Giesser, Barbara, Halper, June, Karpatkin, Herb, Keller, Jennifer, Ng, Alexander V, Pilutti, Lara A, Rohrig, Amanda, Van Asch, Paul, Zackowski, Kathleen, Motl, Robert W

“…To provide clinicians who treat multiple sclerosis (MS) patients with evidence-based or expert opinion-based recommendations for promoting exercise and…”
Get more information

New insights into the burden and costs of multiple sclerosis in Europe by Kobelt, Gisela, Thompson, Alan, Berg, Jenny, Gannedahl, Mia, Eriksson, Jennifer

“…The current focus in multiple sclerosis (MS) is on early diagnosis and drug intervention, with a view to modifying disease progression. Consequently,…”
Get more information

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 by Achiron, Anat, Dolev, Mark, Menascu, Shay, Zohar, Daniela-Noa, Dreyer-Alster, Sapir, Miron, Shmuel, Shirbint, Emanuel, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Polliack, Michael, Falb, Rina, Gurevich, Michael

“…Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be…”
Get more information

Recommendations for cognitive screening and management in multiple sclerosis care by Kalb, Rosalind, Beier, Meghan, Benedict, Ralph Hb, Charvet, Leigh, Costello, Kathleen, Feinstein, Anthony, Gingold, Jeffrey, Goverover, Yael, Halper, June, Harris, Colleen, Kostich, Lori, Krupp, Lauren, Lathi, Ellen, LaRocca, Nicholas, Thrower, Ben, DeLuca, John

“…To promote understanding of cognitive impairment in multiple sclerosis (MS), recommend optimal screening, monitoring, and treatment strategies, and address…”
Get more information

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study by Giovannoni, Gavin, Soelberg Sorensen, Per, Cook, Stuart, Rammohan, Kottil, Rieckmann, Peter, Comi, Giancarlo, Dangond, Fernando, Adeniji, Abidemi K, Vermersch, Patrick

“…In the 2-year CLARITY study, cladribine tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with…”
Get more information

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, Xavier, Gold, Ralf, Thompson, Alan J, Otero-Romero, Susana, Amato, Maria Pia, Chandraratna, Dhia, Clanet, Michel, Comi, Giancarlo, Derfuss, Tobias, Fazekas, Franz, Hartung, Hans Peter, Havrdova, Eva, Hemmer, Bernhard, Kappos, Ludwig, Liblau, Roland, Lubetzki, Catherine, Marcus, Elena, Miller, David H, Olsson, Tomas, Pilling, Steve, Selmaj, Krysztof, Siva, Axel, Sorensen, Per Soelberg, Sormani, Maria Pia, Thalheim, Christoph, Wiendl, Heinz, Zipp, Frauke

“…Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data…”
Get more information

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions by Elliott, Colm, Wolinsky, Jerry S, Hauser, Stephen L, Kappos, Ludwig, Barkhof, Frederik, Bernasconi, Corrado, Wei, Wei, Belachew, Shibeshih, Arnold, Douglas L

“…Chronic lesion activity driven by smoldering inflammation is a pathological hallmark of progressive forms of multiple sclerosis (MS). To develop a method for…”
Get more information

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis by Benedict, Ralph Hb, DeLuca, John, Phillips, Glenn, LaRocca, Nicholas, Hudson, Lynn D, Rudick, Richard

“…Cognitive and motor performance measures are commonly employed in multiple sclerosis (MS) research, particularly when the purpose is to determine the efficacy…”
Get more information

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis by Motl, Robert W, Cohen, Jeffrey A, Benedict, Ralph, Phillips, Glenn, LaRocca, Nicholas, Hudson, Lynn D, Rudick, Richard

“…The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA),…”
Get more information

Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes by Ruano, Luis, Portaccio, Emilio, Goretti, Benedetta, Niccolai, Claudia, Severo, Milton, Patti, Francesco, Cilia, Sabina, Gallo, Paolo, Grossi, Paola, Ghezzi, Angelo, Roscio, Marco, Mattioli, Flavia, Stampatori, Chiara, Trojano, Maria, Viterbo, Rosa Gemma, Amato, Maria Pia

“…There is limited and inconsistent information on the clinical determinants of cognitive impairment (CI) in multiple sclerosis (MS). The aim of this study was…”
Get more information

The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults by de Mol, C L, Wong, Yym, van Pelt, E D, Wokke, Bha, Siepman, Tam, Neuteboom, R F, Hamann, D, Hintzen, R Q

“…The aim of this study was to assess the Dutch nationwide incidence of myelin oligodendrocyte glycoprotein (MOG)-IgG-associated acquired demyelinating syndromes…”
Get more information

Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis by Ramanathan, Sudarshini, Prelog, Kristina, Barnes, Elizabeth H, Tantsis, Esther M, Reddel, Stephen W, Henderson, Andrew P D, Vucic, Steve, Gorman, Mark P, Benson, Leslie A, Alper, Gulay, Riney, Catherine J, Barnett, Michael, Parratt, John D E, Hardy, Todd A, Leventer, Richard J, Merheb, Vera, Nosadini, Margherita, Fung, Victor S C, Brilot, Fabienne, Dale, Russell C

“…Recognizing the cause of optic neuritis (ON) affects treatment decisions and visual outcomes. We aimed to define radiological features of first-episode…”
Get more information

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis by Feys, Peter, Lamers, Ilse, Francis, Gordon, Benedict, Ralph, Phillips, Glenn, LaRocca, Nicholas, Hudson, Lynn D, Rudick, Richard

“…Impaired manual dexterity is a frequently reported disability in people with multiple sclerosis (MS) and is increasingly prevalent with worsening disease…”
Get more information

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity by Högel, Heidi, Rissanen, Eero, Barro, Christian, Matilainen, Markus, Nylund, Marjo, Kuhle, Jens, Airas, Laura

“…Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), have been shown to…”
Get more information

Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis by Calvi, Alberto, Clarke, Margareta A, Prados, Ferran, Chard, Declan, Ciccarelli, Olga, Alberich, Manel, Pareto, Deborah, Rodríguez Barranco, Marta, Sastre-Garriga, Jaume, Tur, Carmen, Rovira, Alex, Barkhof, Frederik

“…Magnetic resonance imaging (MRI) markers for chronic active lesions in MS include slowly expanding lesions (SELs) and paramagnetic rim lesions (PRLs). To…”
Get more information

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis by Hegen, Harald, Walde, Janette, Berek, Klaus, Arrambide, Georgina, Gnanapavan, Sharmilee, Kaplan, Batia, Khalil, Michael, Saadeh, Ruba, Teunissen, Charlotte, Tumani, Hayrettin, Villar, Luisa M, Willrich, Maria Alice V, Zetterberg, Henrik, Deisenhammer, Florian

“…Intrathecal immunoglobulin-G synthesis is a hallmark of multiple sclerosis (MS), which can be detected by oligoclonal IgG bands (OCB) or by κ-free light chains…”
Get more information

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II by Gärtner, Jutta, Hauser, Stephen L, Bar-Or, Amit, Montalban, Xavier, Cohen, Jeffrey A, Cross, Anne H, Deiva, Kumaran, Ganjgahi, Habib, Häring, Dieter A, Li, Bingbing, Pingili, Ratnakar, Ramanathan, Krishnan, Su, Wendy, Willi, Roman, Kieseier, Bernd, Kappos, Ludwig

“…In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic…”
Get more information

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study by Tourbah, Ayman, Lebrun-Frenay, Christine, Edan, Gilles, Clanet, Michel, Papeix, Caroline, Vukusic, Sandra, De Sèze, Jerome, Debouverie, Marc, Gout, Olivier, Clavelou, Pierre, Defer, Gilles, Laplaud, David-Axel, Moreau, Thibault, Labauge, Pierre, Brochet, Bruno, Sedel, Frédéric, Pelletier, Jean

“…Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study. To confirm the efficacy…”
Get more information

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis by Kappos, Ludwig, De Stefano, Nicola, Freedman, Mark S, Cree, Bruce Ac, Radue, Ernst-Wilhelm, Sprenger, Till, Sormani, Maria Pia, Smith, Terence, Häring, Dieter A, Piani Meier, Daniela, Tomic, Davorka

“…'No evidence of disease activity' (NEDA), defined as absence of magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and…”
Get more information